美多巴联合普拉克索治疗对帕金森患者运功功能的影响及安全性分析
|
摘要
目的:探讨美多巴联合普拉克索治疗对帕金森(PD)患者运动功能的影响,并分析其安全性。方法:选择2015年1月至2018年1月于陕西省杨凌示范区医院接受治疗的82例PD患者为研究对象,按照随机数字表法将其均分为实验组与对照组,每组41例。对照组患者采取美多巴进行治疗,实验组患者采取美多巴联合普拉克索治疗,两组患者治疗时间均为12周,比较两组治疗总有效率,以及两组患者治疗前、后帕金森Hoehn-Yahr分期、统一帕金森病评定量表评分中第Ⅲ部分运动检查评分(UPDRSⅢ)、韦氏综合评定量表(Webster评分)和副反应量表(TESS)评分。结果:实验组治疗总有效率为56.10%(23/41),显著高于对照组的39.02%(16/41)(P<0.05)。治疗后,实验组Hoehn-Yahr分期Ⅲ、Ⅳ、Ⅴ期患者比率显著低于对照组,UPDRSⅢ及TESS评分明显低于对照组(均P<0.05)。结论:美多巴联合普拉克索对PD具有良好的治疗效果,同时具有较高的安全性。
Objective:To explore the clinical effect of madopa combined with pramipexole on motor function in patients with Parkinson's disease(PD),and to analyze the safety of treatment.Methods:A total of 82 PD patients treated in our hospital from January 2015 to January 2018 were selected,and randomly divided into an experimental group and a control group,with 41 cases in each group.The patients in the control group were treated with madopa,and those in the experimental group were treated with madopa combined with pramipexole for 12 weeks.The total effective rate,PD Hoehn-Yahr staging,Unified PD Rating Scale(UPDRS)partⅢscore,Webster score and Treatment Emergent Side effect Scale(TESS)score were compared between the two groups.Results:The total effective rate was 56.10%(23/41)in the experimental group and 39.02%(16/41)in the control group,and the difference between the two groups was statistically significant(P<0.05).After treatment,the proportion of patients in Hoehn-Yahr stageⅢ,Ⅳ andⅤ,the UPDRS partⅢscore and TESS score in the experimental group were lower than those in the control group(P<0.05).Conclusion:Medopa combined with pramipexole was effective and safe in the treatment of PD.
Objective:To explore the clinical effect of madopa combined with pramipexole on motor function in patients with Parkinson's disease(PD),and to analyze the safety of treatment.Methods:A total of 82 PD patients treated in our hospital from January 2015 to January 2018 were selected,and randomly divided into an experimental group and a control group,with 41 cases in each group.The patients in the control group were treated with madopa,and those in the experimental group were treated with madopa combined with pramipexole for 12 weeks.The total effective rate,PD Hoehn-Yahr staging,Unified PD Rating Scale(UPDRS)partⅢscore,Webster score and Treatment Emergent Side effect Scale(TESS)score were compared between the two groups.Results:The total effective rate was 56.10%(23/41)in the experimental group and 39.02%(16/41)in the control group,and the difference between the two groups was statistically significant(P<0.05).After treatment,the proportion of patients in Hoehn-Yahr stageⅢ,Ⅳ andⅤ,the UPDRS partⅢscore and TESS score in the experimental group were lower than those in the control group(P<0.05).Conclusion:Medopa combined with pramipexole was effective and safe in the treatment of PD.
引文
[1]原凌云,周以军,朱妮,等.2015年安康市居民期望寿命及寿命损失情况分析[J].职业与健康,2017,33(2):200-202.
[2]MEHDI AA,KARIM AA,MATSANGOS AE,et al.Cellular GFP toxicity and immunogenicity:potential confounders in vivo cell tracking experiments[J].Stem Cell Reviews,2016,12(5):553-559.
[3]刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98-101.
[4]张勇,卢祖能,董红娟,等.帕金森病非运动症状及其治疗的流行病学调查[J].卒中与神经疾病,2016,23(5):343-347.
[5]CERAVOLO R,COSSU G,BANDETTINID PM,et al.Neuropathy and levodopa in Parkinson’s disease:evidence from a multicenter study[J].Movement Disorders,2013,28(10):1391-1397.
[6]张丽.美多芭联合普拉克索治疗帕金森病的有效性及安全性[J].中国实用医药,2017,12(3):121-122.
[7]陈敏,孙涛,陈艳红,等.不同Hoehn-Yahr分级帕金森病患者血浆a-共核蛋白的研究[J].卒中与神经疾病,2015,22(6):323-326.
[8]欧阳莎,许巍.针灸与西药治疗帕金森病疗效比较的系统评价[J].中医药通报,2017,16(1):34-38.
[9]陈涛,田增民,尹丰,等.神经干细胞移植治疗帕金森病的临床研究[J].中国微侵袭神经外科杂志,2012,17(10):452-453.
[10]梅雨晴,黄译腺,恽文伟.同型半胱氨酸与帕金森病相关性研究进展[J].临床神经病学杂志,2014,27(1):72-73.
[11]吕荣祥.美多巴联合普拉克索治疗帕金森病的有效性及安全性研究[J].中国生化药物杂志,2014,19(3):154-155.
[12]张皓春,刘春平,税丽娟,等.美多巴联合普拉克索治疗帕金森病的临床效果分析[J].西部医学,2015,27(6):828-830.
[2]MEHDI AA,KARIM AA,MATSANGOS AE,et al.Cellular GFP toxicity and immunogenicity:potential confounders in vivo cell tracking experiments[J].Stem Cell Reviews,2016,12(5):553-559.
[3]刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98-101.
[4]张勇,卢祖能,董红娟,等.帕金森病非运动症状及其治疗的流行病学调查[J].卒中与神经疾病,2016,23(5):343-347.
[5]CERAVOLO R,COSSU G,BANDETTINID PM,et al.Neuropathy and levodopa in Parkinson’s disease:evidence from a multicenter study[J].Movement Disorders,2013,28(10):1391-1397.
[6]张丽.美多芭联合普拉克索治疗帕金森病的有效性及安全性[J].中国实用医药,2017,12(3):121-122.
[7]陈敏,孙涛,陈艳红,等.不同Hoehn-Yahr分级帕金森病患者血浆a-共核蛋白的研究[J].卒中与神经疾病,2015,22(6):323-326.
[8]欧阳莎,许巍.针灸与西药治疗帕金森病疗效比较的系统评价[J].中医药通报,2017,16(1):34-38.
[9]陈涛,田增民,尹丰,等.神经干细胞移植治疗帕金森病的临床研究[J].中国微侵袭神经外科杂志,2012,17(10):452-453.
[10]梅雨晴,黄译腺,恽文伟.同型半胱氨酸与帕金森病相关性研究进展[J].临床神经病学杂志,2014,27(1):72-73.
[11]吕荣祥.美多巴联合普拉克索治疗帕金森病的有效性及安全性研究[J].中国生化药物杂志,2014,19(3):154-155.
[12]张皓春,刘春平,税丽娟,等.美多巴联合普拉克索治疗帕金森病的临床效果分析[J].西部医学,2015,27(6):828-830.